STAT+: Tango reports 82% tumor response rate in trial of combo therapy for advanced pancreatic cancer
An experimental drug combination led to tumor responses in 82% of patients with a certain type of advanced pancreatic cancer, Tango Therapeutics reported.
<p>An experimental drug combination led to tumor responses in 82% of patients with a certain type of advanced pancreatic cancer, Tango Therapeutics reported.</p>